SCHEMBL8965046

SCHEMBL8965046

CCc1ccc(C=CC(=O)c2ccc(O)cc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F3 P13726 3/20 0.74
MAOB P27338 5/20 0.69
MAPT P10636 6/20 0.69
RAB9A P51151 4/20 0.69
MAOA P21397 2/20 0.69
POLB P06746 1/20 0.69
ABCG2 Q9UNQ0 3/20 0.67
LMNA P02545 3/20 0.64
ESR1 P03372 1/20 0.64
ESR2 Q92731 1/20 0.64
CXCL12 P48061 1/20 0.64
KMT2A Q03164 4/20 0.63
MEN1 O00255 3/20 0.63
ALDH1A1 P00352 2/20 0.63
P4HB P07237 1/20 0.63
CALM1 P0DP23 1/20 0.63
XDH P47989 1/20 0.63
GAA P10253 1/20 0.63
CASP3 P42574 1/20 0.63
SENP8 Q96LD8 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8976977 1.00 F3 (0.74) F3MAOBMAPTRAB9AMAOA
SCHEMBL8965047 1.00 F3 (0.74) F3MAOBMAPTRAB9AMAOA
SCHEMBL8976983 1.00 F3 (0.74) F3MAOBMAPTRAB9AMAOA
SCHEMBL28850948 0.93 MAOB (0.77) F3MAOBMAPTRAB9AMAOA
SCHEMBL11994844 0.93 MAOB (0.77) F3MAOBMAPTRAB9AMAOA
SCHEMBL23082622 0.89 MAOB (0.71) F3MAOBMAPTRAB9AMAOA
SCHEMBL25195124 0.88 F3 (0.70) F3MAOBMAPTRAB9AMAOA
SCHEMBL25219431 0.88 F3 (0.70) F3MAOBMAPTRAB9AMAOA
SCHEMBL25207505 0.87 MAOB (0.69) F3MAOBMAPTRAB9AMAOA
SCHEMBL9338261 0.87 MAPT (0.77) F3MAOBMAPTRAB9AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-5525457-A Copolymers of unsaturated carboxylic acid, an epoxy-functional monomer, and cinnamoylphenyl group-monomer; high halation preventing effect, involves no sublimation of radiation absorbing components contained therein, possesses excellent heat resistance, dry etching performance, storage stability JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1996-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B F3 5/4885MAOB 1004/4885MAPT 3297/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 F3 11/4885MAOB 2435/4885MAPT 3512/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 F3 11/4885MAOB 2435/4885MAPT 3512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.